Cypre positions to deliver in vitro animal-alternatives to the biopharma drug discovery industry with the recent passing of the FDA Modernization Act.
Peer-Reviewed Publication showcases the Cypre 3D in vitro tumor model platform for biopharma drug discovery.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cypre positions to deliver in vitro animal-alternatives to the biopharma drug discovery industry with the recent passing of the FDA Modernization Act. Historically drug testing requires animal models for efficacy and toxicity assessment but the Modernization Act ushers in a new path for in vitro assays.
With services launched in 2022, the Cypre Tumor Panels offer monthly screening of 3D in vitro tumor models from human-only patient-derived xenografts (PDX) or cell lines (CDX). The Cypre models incorporate genomically-annotated tumors, stromal cells (fibroblasts), immune cells (PBMCs), and an extracellular matrix, in a reproducible and scalable multiwell plate format for routine drug screening of small molecules, antibodies, and cell therapies.
The Cypre platform provides a suite of analytics that includes standard efficacy assessments such as tumor size reduction and killing, and nuanced mechanisms such as T cell infiltration and cytokine production. In Cypre’s recent publication in Cells, the authors found that fibroblasts played a critical role in generating an immunosuppressive environment, and the spatial proximity of PBMCs contributed to both the degree of anti-PD1 response and M2 macrophage differentiation. Link to paper.
“We engineer the scaffolding and spatial placement of the TME compartments, allowing the cells to do their job and self-organize into immune-competent tumors. This opens the door for studying the barriers to immunotherapy such as immune exclusion, a significant challenge in therapeutic development,” says the Cypre CEO and Founding Scientist, Kolin Hribar, PhD.
The Cypre Tumor Panels impact multiple stages of drug discovery – lead identification, mechanism of action, and indication selection. As the biopharma and regulatory agencies continue to adopt in vitro models following the FDA Modernization Act, it will be critical to utilize systems that represent complex human tumor biology and the diversity of patient outcomes.
About Cypre
Cypre’s trailblazing 3D in vitro tumor model platform offers its therapeutic partners unique insights into targeted and immuno-therapeutic responses. Reach out to schedule a 30-minute meeting today. www.cypre.co.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005393/en/
Contacts
Investor/Media Contact for Cypre:
Cypre Business Development
bd@cypre.co
Source: Cypre
View this news release online at:
http://www.businesswire.com/news/home/20230523005393/en
